LGND Ligand Pharmaceuticals Incorporated

$182.61

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.

Website: https://www.ligand.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
886163
Address
11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA, CA, US
Valuation
Market Cap
$2.02B
P/E Ratio
nan
PEG Ratio
1.53
Price to Book
2.43
Performance
EPS
$-0.22
Dividend Yield
—
Profit Margin
-2.41%
ROE
-0.53%
Technicals
50D MA
$110.51
200D MA
$108.61
52W High
$129.90
52W Low
$67.72
Fundamentals
Shares Outstanding
19M
Target Price
$143.50
Beta
0.97

LGND EPS Estimates vs Actual

● Estimated
● Actual

LGND News & Sentiment

Oct 01, 2025 • Benzinga SOMEWHAT-BULLISH
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - Boston Scientific ( NYSE:BSX ) , Elutia ( NASDAQ:ELUT )
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market -
Oct 01, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform ...
Sep 29, 2025 • Benzinga SOMEWHAT-BULLISH
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - X4 Pharmaceuticals ( NASDAQ:XFOR ) , Altimmune ( NASDAQ:ALT )
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises
Sep 29, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH ...
Sep 26, 2025 • Zacks Commentary NEUTRAL
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Sep 25, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
Arecor Therapeutics announces Co-development Agreement for AT278 with Sequel Med Tech and Sale of Royalty and Technology Access Fees for up to ...
Sentiment Snapshot

Average Sentiment Score:

0.144
50 articles with scored sentiment

Overall Sentiment:

Neutral

LGND Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.78
  • Whisper: —
  • Surprise %: 0.0%
Feb 25, 2025
Dec 31, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $1.27
  • Estimate: $1.19
  • Whisper: —
  • Surprise %: 6.7%
Nov 07, 2024
Sep 30, 2024 (Pre market)
0.49 Surprise
  • Reported EPS: $1.84
  • Estimate: $1.35
  • Whisper: —
  • Surprise %: 36.3%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.34 Surprise
  • Reported EPS: $1.40
  • Estimate: $1.06
  • Whisper: —
  • Surprise %: 32.1%
May 07, 2024
Mar 31, 2024 (Post market)
0.42 Surprise
  • Reported EPS: $1.20
  • Estimate: $0.78
  • Whisper: —
  • Surprise %: 53.9%
Feb 27, 2024
Dec 31, 2023 (Pre market)
0.72 Surprise
  • Reported EPS: $1.38
  • Estimate: $0.66
  • Whisper: —
  • Surprise %: 109.1%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.41 Surprise
  • Reported EPS: $1.02
  • Estimate: $0.61
  • Whisper: —
  • Surprise %: 67.2%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.78 Surprise
  • Reported EPS: $1.42
  • Estimate: $0.64
  • Whisper: —
  • Surprise %: 121.9%
May 04, 2023
Mar 31, 2023 (Post market)
1.39 Surprise
  • Reported EPS: $2.28
  • Estimate: $0.89
  • Whisper: —
  • Surprise %: 156.2%

Financials